CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
Category: #health  By Saipriya Iyer  Date: 2020-09-07
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec Group (CNBG) has recently announced that nearly 50,000 patients from across various countries will be enrolled in Phase 3 clinical studies of its COVID-19 vaccine. The Chinese biotechnology firm said in a statement that its lead COVID-19 vaccine candidate will be tested in countries like Bahrain, UAE, Peru, Morocco, Argentina among others.

Both Sinovac Biotech Ltd. and CNBG have revealed that they each have come across two more nations to conduct their late-stage clinical tests. While Pakistan and Serbia have agreed to take part in CNBG’s study, countries like Bangladesh and Turkey have decided to go with Sinovac’s vaccine trials as China decides to boost its efforts to attain an effective vaccine for COVID-19.

As per international media reports, Serbia will test two CNBG vaccines that are being developed in Beijing and Wuhan. Meanwhile, Pakistan is planning to test the vaccine from the laboratory of the Beijing unit.

Speaking on the move, Zhang Yuntao, Vice President, CNBG, said that apart from the active involvement from nearly 10 countries in its Phase 3 clinical studies, the company has also received an overwhelming response from various other foreign countries, with cumulative orders racking up to 500 million doses of its vaccines.

However, CNBG at this point can produce around 300 million doses of its lead vaccine candidate per year. This number is anticipated to be attainable after the overhaul of its existing manufacturing techniques.

As for Dr. Soumya Swaminathan, Chief Scientist, World Health Organization (WHO), the global distribution of the coronavirus vaccine on a large scale will likely take place by the second quarter or third quarter of 2021. By then, countries might see doses flowing in their healthcare sectors to initiate immunization of their population

Source Credit: https://www.republicworld.com/world-news/china/covid-19-vaccine-phase-3-clinical-trial-developed-by-china-to-include.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...